CN102007129B - 用作治疗人类脑疾病的前药的雪花胺衍生物 - Google Patents

用作治疗人类脑疾病的前药的雪花胺衍生物 Download PDF

Info

Publication number
CN102007129B
CN102007129B CN200880128608.5A CN200880128608A CN102007129B CN 102007129 B CN102007129 B CN 102007129B CN 200880128608 A CN200880128608 A CN 200880128608A CN 102007129 B CN102007129 B CN 102007129B
Authority
CN
China
Prior art keywords
brain
galantamine
galanthamine
disease
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880128608.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102007129A (zh
Inventor
A·马埃利科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurodyn Life Sciences Inc
Original Assignee
Neurodyn Life Sciences Inc
Galantos Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102007129(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurodyn Life Sciences Inc, Galantos Pharma GmbH filed Critical Neurodyn Life Sciences Inc
Publication of CN102007129A publication Critical patent/CN102007129A/zh
Application granted granted Critical
Publication of CN102007129B publication Critical patent/CN102007129B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200880128608.5A 2008-04-14 2008-04-14 用作治疗人类脑疾病的前药的雪花胺衍生物 Active CN102007129B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/002929 WO2009127218A1 (en) 2008-04-14 2008-04-14 Derivatives of galantamine as pro-drugs for the treatment of human brain diseases

Publications (2)

Publication Number Publication Date
CN102007129A CN102007129A (zh) 2011-04-06
CN102007129B true CN102007129B (zh) 2014-05-07

Family

ID=40019199

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880128608.5A Active CN102007129B (zh) 2008-04-14 2008-04-14 用作治疗人类脑疾病的前药的雪花胺衍生物

Country Status (8)

Country Link
EP (1) EP2137192B8 (enExample)
JP (1) JP5504253B2 (enExample)
CN (1) CN102007129B (enExample)
CA (1) CA2721007C (enExample)
DK (1) DK2137192T3 (enExample)
ES (1) ES2463715T3 (enExample)
PL (1) PL2137192T3 (enExample)
WO (1) WO2009127218A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700473T3 (es) * 2012-07-27 2019-02-18 Neurodyn Life Sciences Inc Biodisponibilidad cerebral mejorada de galantamina mediante formulaciones seleccionadas y administración transmucosa de profármacos lipofílicos
ES2880399T3 (es) 2012-07-27 2021-11-24 Neurodyn Life Sciences Inc Biodisponibilidad cerebral mejorada de galantamina mediante formulaciones seleccionadas y administración transmucosa de profármacos lipofílicos
WO2015148480A1 (en) 2014-03-25 2015-10-01 Emicipi Llc Treatment of rett syndrome
US10561665B2 (en) * 2014-03-25 2020-02-18 Synaptec Development Llc Treatment of autism
AU2015258814B2 (en) * 2014-05-16 2018-04-05 Synaptec Development Llc Clearance of amyloid ss
EP4029867A1 (en) 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate
EP4186509A1 (en) 2021-11-26 2023-05-31 Alpha Cognition Inc. Alpha-1062 for treating traumatic brain injury
US12208167B1 (en) 2024-02-06 2025-01-28 Alpha Cognition Inc. Coated tablets for pH-dependent release of benzgalantamine
US12551491B1 (en) * 2025-07-23 2026-02-17 Alpha Cognition Inc. Dosage regimens for benzgalantamine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021561A1 (en) * 1997-10-29 1999-05-06 Davis Bonnie M Method for treatment of disorders of attention
EP1777222A1 (en) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3856594D1 (de) 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
AU1430099A (en) 1998-12-01 2000-06-19 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage
AU780012B2 (en) 1999-12-10 2005-02-24 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
CN1380883A (zh) 2000-03-31 2002-11-20 萨诺化学药物股份公司 雪花胺的新衍生物和类似物
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US7307162B2 (en) 2003-09-26 2007-12-11 Scinopharm Taiwan, Ltd. Resolution of a narwedine amide derivative
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021561A1 (en) * 1997-10-29 1999-05-06 Davis Bonnie M Method for treatment of disorders of attention
EP1777222A1 (en) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SYNTHESIS AND BIOLOGICAL ACTIVITY OF GALANTHAMINE DERIVATIVES AS ACETYLCHOLINESTERASE (AChE) INHIBITORS;So-Yeop Han, et al.;《Bioorganic & Medicinal Chemistry Letter》;19911231;第1卷(第11期);579-580 *

Also Published As

Publication number Publication date
DK2137192T3 (da) 2014-05-26
JP2011516588A (ja) 2011-05-26
ES2463715T3 (es) 2014-05-29
CN102007129A (zh) 2011-04-06
CA2721007C (en) 2014-04-29
WO2009127218A1 (en) 2009-10-22
EP2137192B1 (en) 2014-02-19
EP2137192A1 (en) 2009-12-30
JP5504253B2 (ja) 2014-05-28
PL2137192T3 (pl) 2014-07-31
EP2137192B8 (en) 2014-06-11
CA2721007A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
CN102007129A (zh) 用作治疗人类脑疾病的前药的雪花胺衍生物
CA3019663C (en) IVACAFTOR ANALOGUES CONTAINING SILICONE ATOMS
JP6371786B2 (ja) プロテアソーム活性を向上させるための組成物および方法
US20130210808A1 (en) Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2016105484A1 (en) Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
Mitscher Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents
ES2539859T3 (es) Nuevo derivado de aminodihidrotiazina condensado
EP3116501A1 (en) Compounds, compositions, and methods for increasing cftr activity
WO2016105468A1 (en) Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
FR2926556A1 (fr) Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
US10822377B2 (en) Substituted urea depsipeptide analogs as activators of the ClpP endopeptidase
ES2348334T3 (es) Potenciadores colinérgicos con permeabilidad de la barrera hematoencefálica mejorada para el tratamiento de enfermedades acompañadas de deterioro cognitivo.
AU2014342593B2 (en) N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
US20250263412A1 (en) Non-hydroxamate hdac6 inhibitors and related methods of use
CA3218824A1 (en) Stapled peptides and methods thereof
AU2016281225A1 (en) Substituted dihydropyrrolopyrazole derivative
WO2025007938A1 (zh) 一类细胞程序性坏死抑制剂及其制备方法和用途
Naveen et al. Concise total synthesis of water soluble metatacarboline A, C, D, E and F and its anticancer activity
Essig et al. Predictive Bioinformatic Assignment of Methyl-Bearing Stereocenters, Total Synthesis, and an Additional Molecular Target of Ajudazol B
KR102603671B1 (ko) 치환된 3-디알킬아미노메틸-피페리딘-4-일-벤즈아미드 및 이를 제조 및 사용하는 방법
JP2002540197A (ja) 抗菌剤
BR112019015834A2 (pt) Compostos, composição farmacêutica, kit e uso de um composto ou uma composição
Wang et al. Synthesis and biological evaluation of a peptide-remifentanil conjugate as a novel bifunctional mu/delta-opioid receptor agonist for the treatment of pain
DE69626846T2 (de) Phosphonsäurederivate mit metallopeptidase inhibierender aktivität
US10975099B2 (en) Thiophene compounds for long-acting injectable compositions and related methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NEURAL DYNAMIC LIFE SCIENCE CO., LTD.

Free format text: FORMER OWNER: GALANTOS PHARMA GMBH

Effective date: 20131212

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20131212

Address after: Charlottetown Canada

Applicant after: NEURODYN LIFE SCIENCES INC

Address before: Mainz, Germany

Applicant before: Galantos Pharma GmbH

C14 Grant of patent or utility model
GR01 Patent grant